[go: up one dir, main page]

TWI370735B - Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome - Google Patents

Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome

Info

Publication number
TWI370735B
TWI370735B TW096144583A TW96144583A TWI370735B TW I370735 B TWI370735 B TW I370735B TW 096144583 A TW096144583 A TW 096144583A TW 96144583 A TW96144583 A TW 96144583A TW I370735 B TWI370735 B TW I370735B
Authority
TW
Taiwan
Prior art keywords
agomelatine
smith
treatment
magenis syndrome
medicaments intended
Prior art date
Application number
TW096144583A
Other languages
English (en)
Other versions
TW200829237A (en
Inventor
Elisabeth Mocaer
Agnes Fabiano
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI370735(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of TW200829237A publication Critical patent/TW200829237A/zh
Application granted granted Critical
Publication of TWI370735B publication Critical patent/TWI370735B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Primary Cells (AREA)
  • Connection Of Batteries Or Terminals (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW096144583A 2006-11-24 2007-11-23 Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome TWI370735B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610296A FR2908995B1 (fr) 2006-11-24 2006-11-24 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis

Publications (2)

Publication Number Publication Date
TW200829237A TW200829237A (en) 2008-07-16
TWI370735B true TWI370735B (en) 2012-08-21

Family

ID=38229648

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096144583A TWI370735B (en) 2006-11-24 2007-11-23 Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome

Country Status (38)

Country Link
US (1) US20080132577A1 (zh)
EP (1) EP1929999B1 (zh)
JP (1) JP2008127395A (zh)
KR (2) KR20080047299A (zh)
CN (1) CN101194901A (zh)
AR (1) AR063896A1 (zh)
AT (1) ATE501717T1 (zh)
AU (1) AU2007234614B2 (zh)
BR (1) BRPI0704453A2 (zh)
CA (1) CA2610638C (zh)
CL (1) CL2007003396A1 (zh)
CY (1) CY1111430T1 (zh)
DE (1) DE602007013166D1 (zh)
DK (1) DK1929999T3 (zh)
EA (1) EA013471B1 (zh)
ES (1) ES2363252T3 (zh)
FR (1) FR2908995B1 (zh)
GE (1) GEP20094746B (zh)
HR (1) HRP20110370T1 (zh)
JO (1) JO2656B1 (zh)
MA (1) MA29523B1 (zh)
ME (1) ME01959B (zh)
MX (1) MX2007014199A (zh)
MY (1) MY145139A (zh)
NO (1) NO338951B1 (zh)
NZ (1) NZ563684A (zh)
PE (1) PE20081347A1 (zh)
PL (1) PL1929999T3 (zh)
PT (1) PT1929999E (zh)
RS (1) RS51676B (zh)
SA (1) SA07280635B1 (zh)
SG (1) SG143203A1 (zh)
SI (1) SI1929999T1 (zh)
TW (1) TWI370735B (zh)
UA (1) UA94042C2 (zh)
UY (1) UY30704A1 (zh)
WO (1) WO2008071870A2 (zh)
ZA (1) ZA200710103B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2810647A1 (en) * 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
JP6866379B2 (ja) * 2016-01-26 2021-04-28 アナベックス ライフ サイエンシズ コーポレイション 神経発達障害療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1564202A (en) * 1924-05-20 1925-12-08 Christensen Jens Herman Method of producing water-insoluble multicolored screens
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine

Also Published As

Publication number Publication date
CA2610638C (fr) 2013-07-30
TW200829237A (en) 2008-07-16
PL1929999T3 (pl) 2011-06-30
CA2610638A1 (fr) 2008-05-24
NZ563684A (en) 2009-04-30
EA013471B1 (ru) 2010-04-30
WO2008071870A2 (fr) 2008-06-19
UA94042C2 (ru) 2011-04-11
ATE501717T1 (de) 2011-04-15
HRP20110370T1 (hr) 2011-06-30
ZA200710103B (en) 2008-11-26
NO20075989L (no) 2008-05-26
UY30704A1 (es) 2008-01-02
PT1929999E (pt) 2011-04-08
RS51676B (sr) 2011-10-31
PE20081347A1 (es) 2008-11-01
MY145139A (en) 2011-12-30
EA200702318A1 (ru) 2008-06-30
US20080132577A1 (en) 2008-06-05
WO2008071870A3 (fr) 2008-08-14
DE602007013166D1 (de) 2011-04-28
EP1929999A1 (fr) 2008-06-11
JP2008127395A (ja) 2008-06-05
AU2007234614A1 (en) 2008-06-12
MA29523B1 (fr) 2008-06-02
AR063896A1 (es) 2009-02-25
ME01959B (me) 2011-10-31
DK1929999T3 (da) 2011-06-27
CL2007003396A1 (es) 2008-07-25
MX2007014199A (es) 2009-02-11
ES2363252T3 (es) 2011-07-28
KR20110086673A (ko) 2011-07-29
FR2908995A1 (fr) 2008-05-30
CN101194901A (zh) 2008-06-11
GEP20094746B (en) 2009-07-27
AU2007234614B2 (en) 2012-06-14
NO338951B1 (no) 2016-11-07
JO2656B1 (en) 2012-06-17
EP1929999B1 (fr) 2011-03-16
CY1111430T1 (el) 2015-08-05
SG143203A1 (en) 2008-06-27
SA07280635B1 (ar) 2011-10-03
SI1929999T1 (sl) 2011-06-30
KR20080047299A (ko) 2008-05-28
FR2908995B1 (fr) 2009-02-06
BRPI0704453A2 (pt) 2009-09-08

Similar Documents

Publication Publication Date Title
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
ZA200808409B (en) Use of rasagiline for the treatment of restless legs syndrome
EP1971278A4 (en) PROCESS FOR SURFACE TREATMENT OF THE SKIN
PL1978947T3 (pl) Nitrooksypochodne do zastosowania w leczeniu dystrofii mięśniowych
AP2965A (en) Therapeutic compositions and the use thereof
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
LT2068889T (lt) Anakinra, naudojama bronchiolito obliteranso sindromo gydymui
AP2490A (en) Therapeutic compositions and the use thereof
AP2488A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
IL212672A (en) Cycloandesdepsipeptide compounds and their use in drug production
IL218851A0 (en) Use of dimiracetam in the treatment of chronic pain
TWI370735B (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
AP2008004379A0 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorder in the depressed patient
ZA201005875B (en) Use of interleukin-1 conjugates in the treatment of diabetes
EP1982724A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF METABOLIC SYNDROME AND FOODS CONTAINING THE SAME
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
AP2656A (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
EP1956001A4 (en) PHARMACEUTICAL PRODUCT FOR USE IN THE TREATMENT OF URETEROLITHIASE
ZA200702866B (en) Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders
ZA201000469B (en) Therapeutic compositions and the use thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees